Thymalin: a thymic peptide complex, and the family of bioregulators it belongs to
The most cited compound in a family of about a dozen that share a protocol, an evidence base and a single research lineage. This page covers the family as well as the compound, because the arguments for and against are the same for all of them.
Regulatory status. Research compound — no FDA approval. Used clinically in Russia for decades. That is the app’s own field, reproduced here rather than summarised. It means no regulator has reviewed a manufacturer’s evidence for identity, purity, potency or safety in people for this compound, so nothing below is a marketing claim about a product you can buy.
Purity, identity and concentration are therefore unverified by anyone but whoever made the vial. The storage rule in the fact box below is general practice for this formulation rather than a specification for a particular product: General handling practice for this formulation. Your supplier’s own insert or COA overrides anything here.
This page names no vendor, no clinic and no testing service, and there is no discount code anywhere on this site — the moment a page like this recommends where to buy, it stops being information.
- Also known as
- Thymus peptide complex
- Class
- Peptide
- Regulatory status
- Research compound — no FDA approval. Used clinically in Russia for decades.
- Before mixing
- Sealed powder tolerates room temperature in transit, but keep it refrigerated at 2–8 °C (36–46 °F) for anything beyond a few weeks, or frozen for months. Keep it dark — the carton it shipped in is doing a job.
- After mixing
- Once reconstituted with bacteriostatic water: refrigerate at 2–8 °C and use within about 28 days. The benzyl alcohol in bacteriostatic water is what buys that window — plain sterile water has no preservative, so a vial mixed with it should be treated as one sitting only. Kits are usually ten vials: only the one you mixed is on that 28-day clock — the sealed ones keep their own, much longer shelf life, so store them as powder, not as solution.
- What ruins it
- Do not freeze a reconstituted vial. Repeated freeze–thaw is one of the more reliable ways to degrade a peptide.
- Handling caveat
- General handling practice for this formulation. Your supplier’s own insert or COA overrides anything here.
What the bioregulator family is
Animal-only or theoretical The Khavinson bioregulators are short peptide preparations, each derived from or modelled on a specific organ — thymus, pineal, vascular tissue, cartilage, bone marrow, lung — on the premise that each carries tissue-specific regulatory information and restores function in that organ. Thymalin is the thymic one; epithalon is the pineal one and the best known.
They share almost everything: a ten-day course repeated once or twice a year, an identical regulatory position, and a research base concentrated almost entirely in one programme. The app holds around a dozen of them and their entries differ mainly in which organ is named. That is the honest description, and it is why this site publishes two of them rather than twelve near-identical pages.
Thymalin itself is a polypeptide complex rather than a defined molecule, which the app’s drawbacks list flags as a standardisation problem. That distinguishes it from the synthetic tetrapeptides in the same family and puts it closer to cerebrolysin in kind.
The thymus premise, and the mortality follow-up
Established clinical use The biological starting point is real. The thymus involutes after puberty, output of naive T cells falls steadily, and that decline is a well-characterised component of immune ageing. Restoring thymic function is a legitimate target — other groups pursue it with growth hormone and with thymic transplantation.
Animal-only or theoretical The finding most often cited for thymalin is a long-term follow-up of older adults reporting substantially reduced mortality in treated groups over a period of years. If that result were robust it would be among the most important findings in geroscience. The reasons to hold it loosely are the design — allocation, blinding and outcome ascertainment do not meet the standard a contemporary trial would be held to — and the concentration of the work in the group that produced it. Independent replication is what is missing rather than what has failed.
That combination, a large claimed effect from a single lineage with methodological limits, is the same situation the epithalon page describes. It is a reason for interest and not a basis for confidence.
Practical position
There is no approved product outside the country where the research was done, and what is available elsewhere is research-supply material with identity and purity resting on whoever made it — more so for a polypeptide complex than for a defined peptide, because there is less to verify against. This site names no vendor or testing service.
The app records a complete blood count with differential and infection frequency, which is a reasonable way to look for an immune effect and is not a validated marker of one. The app’s own drawbacks list makes the useful observation that effects are most pronounced in older or immunocompromised people and subtle in the young and healthy — which is what a restorative intervention should look like, and also what a null result looks like in a group with nothing to restore.
Anyone with an autoimmune condition or on immunosuppressive therapy should treat a T-cell-directed compound as a conversation with the clinician managing that, as with thymosin alpha-1.
The dosing rows the app records
Off-label or community practice Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.
| Label | Amount | Route and frequency | Duration recorded |
|---|---|---|---|
| Immune and Longevity | 10mg/day | SubQ daily for 10 days, 1-2x per year | 10-day pulse cycles annually |
What the app monitors alongside it
The panel below is the app’s own monitoring note for Thymalin, verbatim. None of the analytes it names has a page here yet.
- Monitoring panel
- CBC with differential (immune cell assessment), infection frequency tracking, inflammatory markers.
Drawbacks and risks the app records
From the app’s own entry, and it is candid: limited Western replication and standardisation difficulty are the two things that constrain everything else here.
- Research primarily from Russia — limited Western replication
- Polypeptide complex — harder to standardize
- Not FDA approved
- Sourcing quality critical
- Most dramatic effects in older or immunocompromised individuals
- Subtle effects in young healthy individuals
Questions people actually ask
Why does this site publish only two of the bioregulators?
Because their app entries differ mainly in which organ is named, and a dozen near-identical pages would be thin content by construction. Thymalin and epithalon are the two with distinct enough evidence and search interest to justify separate pages.
Is the mortality finding credible?
It is published and it comes from one research lineage, with a design that does not meet contemporary trial standards on allocation, blinding and outcome ascertainment. The effect size claimed is large enough that those limitations matter a great deal.
Is thymus decline real?
Yes — thymic involution and falling naive T-cell output are well-characterised parts of immune ageing. Whether this preparation reverses any of it is the separate question.
How does it compare with thymosin alpha-1?
Thymosin alpha-1 is a defined 28-amino-acid peptide with approvals in dozens of countries and hepatitis trial data behind it. Thymalin is an undefined polypeptide complex with a single-lineage evidence base. They are not equivalent.
Where the load-bearing numbers come from
Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.
- Thymic involution and immune ageing
- Established immunology; naive T-cell output declines steadily after puberty
- Long-term mortality follow-up
- Published by the Russian bioregulator programme; design does not meet contemporary trial standards
- Family composition and shared protocol
- app.html holds around a dozen bioregulator entries sharing a ten-day pulse schedule and regulatory status
- Absence of pharmacokinetic data
- app.html holds no half-life or time-to-peak entry, which is why no such rows appear above
A ten-day course once or twice a year is the schedule nobody remembers the dates of. TherapyLog keeps them.
Save this dose to your log